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12 Abstract Epstein-Barr virus (EBV) has been implicated in
13 multiple sclerosis (MS) pathogenesis. We aimed to assess
14 the frequency of EBV-specific IgG and IgM oligoclonal bands
15 (OCB) in cerebrospinal fluid (CSF) of 50 patients with clini-
16 cally isolated syndrome (CIS) and in 27 controls with
17 Guillain-Barré syndrome (GBS). Furthermore, we assessed
18 correlations between the presence of OCB and CIS patients’
19 CSF, MRI, and clinical variables. There was no difference in
20 the proportion of CIS and GB patients with positivity for anti-
21 EBV-specific IgG/IgM OCB. There were no correlations be-
22 tween OCB and analyzed variables, nor were they predictive
23 of a higher disability at 3 years.
24 Keywords Epstein-Barr virus .Clinically isolated syndrome .
25 Multiple sclerosis . Oligoclonal IgG bands . Oligoclonal IgM
26 bands
27 Introduction
28 Epidemiological data, including a seroprevalence >99% in
29 multiple sclerosis (MS) patients (compared to 94% in
30controls) (Ascherio and Munger 2007) and a higher risk of
31MS in subjects with a history of infectious mononucleosis
32(Handel et al. 2010), indicates that EBV may play a role in
33MS pathogenesis. The high infection prevalence in MS pa-
34tients has suggested that it may be a prerequisite for the de-
35velopment of MS, although pathogenetic mechanisms are still
36unclear and hypotheses include promotion of autoimmunity
37by EBV-infected autoreactive B cells, bystander damage re-
38lated to anti-EBV responses, and cross-reactivity between
39EBV and central nervous system (CNS) antigens (Holmøy,
40Kvale, and Vartdal 2004; Lang et al. 2002; Lünemann et al.
412008).
42A debated issue is whether EBV represents an antigenic
43target for antibody production within the CNS.
44Castellazzi et al. (Castellazzi et al. 2014) recently re-
45ported, among other findings, that local synthesis of cere-
46brospinal fluid (CSF) specific IgG oligoclonal bands
47(OCB) directed against Epstein-Barr virus (EBV) occurred
48in 21% of 100 patients with relapsing-remitting multiple
49sclerosis (RRMS), and that they had a low affinity in all
50patients. Authors concluded that the EBV-specific intrathe-
51cal oligoclonal IgG production is probably unrelated to the
52cause of the disease, but may occur in a subset of MS
53patients as part of a humoral polyreactivity directed against
54many different pathogens.
55We hereby report on similar findings in a group of 50
56patients with clinically isolated syndrome (CIS). We further-
57more report results on the frequency of CSF-restricted EBV-
58specific IgM OCB in the CIS cohort, on the correlations be-
59tween the presence of anti-EBV-specific IgG and IgM bands
60and CSF, MRI and clinical variables (including disability and
61the risk of conversion to clinically definite MS within the
62subsequent 3 years), and on the frequency of EBV-specific
63IgG and IgM OCB in a control group of 27 patients with
64Guillain-Barré syndrome (GBS).
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65 Methods and materials
66 Patients
67 Of 201 consecutive patients with a first demyelinating event
68 (CIS) seen at our center, whose CSF and serum had been
69 stored at −80 °C after collection, we selected those patients
70 (nr = 50) who proved positive for both CSF-restricted IgG
71 OCB and CSF IgM OCB (the latter were CSF-restricted in
72 40 patients and present as a “mirror pattern”, i.e., identical
73 bands in CSF and serum, in 10 patients). Furthermore, of 38
74 patients diagnosed with GBS, we selected 27, who showed a
75 CSF IgG mirror pattern, as controls.
76 Data collection
77 Of all CIS patients, we recorded demographic (sex, age at
78 onset), clinical (symptoms at onset, EDSS at onset, and clin-
79 ical recovery), MRI (presence and number of brain and spinal
80 cord MRI lesions, presence and number of gadolinium-
81 enhancing lesions on MRI, and presence of spinal/
82 infratentorial lesions), and routine CSF data collected at onset
83 (CSF proteins, cell count, Link’s IgG Index, presence of IgG
84 OCB and CSF/serum albumin quotient, indicating a blood-
85 brain barrier dysfunction if value >6.5 × 103), as well as
86 follow-up data including the occurrence of relapses and dis-
87 ability status (EDSS) (Kurtzke 1983) in the subsequent
88 3 years.
89 Laboratory procedures
90 Cerebrospinal fluid and serum sampling
91 Laboratory procedures were carried out on CSF, and serum
92 samples from each patient, which, at the time of the diagnostic
93 spinal tap, had been centrifuged at 3000 rpm for 10 min and
94 stored in cryovial tubes at −80 °C within 2 h from collection.
95 CSF and serum samples were analyzed for the presence of
96 IgM OCB by means of agarose gel isoelectric focusing (IEF)
97 followed by immunoblotting with polyclonal specific anti-
98 human IgM antibodies (Dako), according to the method pro-
99 posed by Villar et al. (L. M. Villar et al. 2001), with some
100 modifications (Ferraro et al. 2015). We obtained the approval
101 of the Modena Ethics Committee (protocol nr. 116/09).
102 EBVantigen-specific immunoblotting
103 EBV-specific OCB were investigated by antigen-specific im-
104 munoblotting as reported by Castellazzi et al. (Castellazzi
105 et al. 2014), using the same mixture of antigens (Genway
106 Biotech, Inc. San Diego, CA, USA, a P3H3 extract crude viral
107 lysate containing a high concentration of EBV antigens, in-
108 cluding VCA, EBNA, early antigen diffuse, and early antigen
109restricted). However, we did not use a commercial kit to carry
110out IEF. For IEF, we used agarose gel, polyvinylidene fluoride
111membrane, rabbit anti-human IgG (primary antibody), poly-
112clonal swine anti-rabbit Ig/AP (secondary antibody conjugat-
113ed to alcaline phosphatase) (Dako Cytomation), and nitro blue
114tetrazolium and bromo-cloroindoleyl phosphate as dyes.
115The presence of CSF IgM OCB and of EBV-specific IgG
116and IgM OCB (at least two) was blindly assessed by two
117independent neurologists (DF and PS) and by a biologist
118(RB) in case of discrepancies.
119Statistical methods
120We calculated absolute frequencies and percentages for cate-
121gorical variables and mean ± standard deviation and median
122for continuous variables. Mann-Whitney’s test and Fisher’s
123exact test were used to explore differences between groups.
124We used logistic regression to assess the relationship between
125anti-EBV-specific OCB status and the risk of disability or of a
126relapse (with subsequent diagnosis of clinically definite MS-
127CDMS) at 1 and 3 years in CIS patients.
128Results
129CIS and GBS patient characteristics
130CIS patients’ demographic, clinical, MRI, and CSF character-
131istics are shown in Table 1.
132CIS patients with positivity for IgM OCB, and thus select-
133ed for this study, do not differ from IgM OCB-negative pa-
134tients of the initial CIS cohort (nr = 201) with respect to base-
135line variables, except for a higher number of gadolinium-
136enhancing lesions on baseline MRI in IgM OCB-positive pa-
137tients (1.1 vs 0.5, p = 0.01).
138GBS patients’ demographic and CSF characteristics are
139shown in Table 2.
140Frequency of EBV-specific IgG and IgM in CIS and GBS
141patients
142In CIS, CSF-restricted EBV-specific IgG OCB (see Fig. 1)
143were present in 14 (28%) of patients and a EBV-specific IgG
144OCB in a mirror pattern in three (11%), while CSF-restricted
145EBV-specific IgM OCB (Fig. 2) were present in three (6%).
146In GBS, EBV-specific IgGOCB (mirror pattern) were pres-
147ent in six (22 %) of patients, while EBV-specific IgM OCB
148were present in three (16 %).
149There were no statistically significant differences in the
150proportion of CIS and GB patients with positivity for EBV-
151specific IgG OCB or IgM OCB (p = 0.78 and p = 0.34,
152respectively).
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153 Correlations between EBV-specific IgG/IgM OCB
154 and clinical, MRI, and CSF parameters in CIS patients
155 There were no differences in baseline clinical, MRI, and CSF
156 variables between EBV-specific IgG OCB positive and nega-
157 tive patients, except for a higher mean number of CSF cells in
158 EBV-specific IgG OCB-negative patients; there were no dif-
159 ferences in follow-up data (Table 3). EBV-specific IgM OCB
160positive patients did not differ from EBV-specific IgM OCB-
161negative patients with regard to baseline and follow-up data
162(data not shown).
t1:1 Table 1 BaselineQ2 demographic, clinical, MRI, and CSF characteristics
of CIS patients (nr = 50)
t1:2 Sex M/F 14/36
t1:3 Age at onset, years* 33 ± 9
t1:4 Symptoms at onset
t1:5 ON, n (%)
Sensory, n (%)
Motor/sensory motor, n (%)
Brainstem/cerebellum, n (%)
Other, n (%)
16 (32)
12 (24)
6 (12)
13 (26)
3 (6)
t1:6 Spinal onset, yes/no 18/32
t1:7 EDSS at onset* 2.3 ± 1
t1:8 Complete recovery, n (%) 41 (82)
t1:9 Baseline brain MRI
t1:10 0 lesions, n (%)
1–2 lesions, n (%)
>2lesions, n (%)
Presence of infratentorial lesions, n (%)
Presence of CE, n (%)
4 (8)
7 (14)
39 (78)
25 (50)
26 (54)
t1:11 Baseline spinal cord MRI (available in 26 patients)
t1:12 Positive (at least one lesion), n (%) 20 (77)
t1:13 Total CSF protein* (normal value 15–45 mg/dl)
Patients with elevated CSF protein, n (%)
38.5 ± 12
13 (28)
t1:14 Cells* (normal value <4/mm3)
Patients with elevated CSF cells, n (%)
7.2 ± 8
30 (63)
t1:15 CSF/serum albumin* (normal value <6.5)
Patients with elevated CSF serum/albumin, n (%)
4.1 ± 1.3
3 (6)
t1:16 IgG index* (normal value <0.7)
Patients with elevated IgG index, n (%)
1.2 ± 0.5
45 (92)
ON optic neuritis, CE contrast enhancement
*Values expressed as mean ± SD
Fig. 1 EBV-specific IgG OCB in a CIS patient. Identical amounts of
serum (S) and cerebrospinal fluid (CSF) IgG were isoelectrically
focused and transferred to uncoated membrane (left) or membrane
coated with EBV viral antigens (right). The figure shows a CIS patient
with positivity for CSF-restricted IgG OCB (left) and for EBV-specific
IgG OCB (right)
Fig. 2 EBV-specific IgM OCB in a CIS patient. The figure shows the
CSF and serum of one CIS patient with positivity for CSF-restricted IgM
OCB (left) and EBV-specific IgM OCB (right)
t2:1 Table 2 Demographic and CSF characteristics of GBS patients
(nr = 27)
t2:2 Sex M/F 18/9
t2:3 Age at onset, years* 54 ± 17
t2:4 Total CSF protein* (normal value 15–45 mg/dl)
Patients with elevated CSF protein, n (%)
91 ± 49
23 (85)
t2:5 Cells* (normal value <4/mm3)
Patients with elevated CSF cells, n (%)
32 ± 124
7 (26)
t2:6 CSF/serum albumin* (normal value <6.5)
Patients with elevated CSF serum/albumin, n (%)
14.1 ± 9.7
23 (85)
*Values expressed as mean ± SD
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163 Patients with EBV-specific IgG and IgMOCB did not have
164 a higher risk of conversion to CDMS at 1 or 3 years or of a
165 higher disability at 3 years at logistic regression analysis (data
166 not shown).
167 Discussion
168 In the present study, we found no differences in the proportion
169 of CIS and GB patients with positivity for anti-EBV-specific
170 IgG or IgM OCB. EBV-specific CSF OCB were reported in a
171 variable proportion of MS patients (Cepok et al. 2005;
172 Franciotta et al. 2011; Rand et al. 2000; Virtanen et al.
173 2014), though, in part, they were not CSF-restricted but pres-
174 ent in both serum and CSF (Franciotta et al. 2011; Rand et al.
175 2000; Virtanen et al. 2014).
176 With regard to EBV-specific intrathecal IgG synthesis, as
177 measured by CSF-to-serum antibody indices, some studies
178 found no evidence for increased frequency of intrathecal an-
179 tibody production against EBV in MS patients compared to
180 controls (Jafari et al. 2010), or compared to the response to
181 other viruses (Pohl et al. 2010), while another found such
182evidence only early in the disease course, i.e., within 1 year
183from onset (Jaquiéry et al. 2010).
184The present study, carried out early in the disease course, at
185the time of the first demyelinating event (median interval be-
186tween clinical onset and spinal tap, 2 weeks; range, 0–
1875 months), shows that the intrathecal synthesis of EBV-
188specific IgG OCB is present only in a proportion of patients
189with CIS and the frequency of EBV-specific IgG OCB in the
190CSF of CIS patients does not differ from that of control sub-
191jects with GBS. Clearly, CSF anti-EBV OCB in CIS patients
192differ from those found in GBS patients, since they are CSF-
193restricted in CIS patients, and present in “a mirror pattern”
194(with identical bands in serum, indicating passive transfer
195from serum to CSF) in GBS patients. This is, however, what
196we would expect in case of an intrathecal antibody production
197against a target antigen within the CNS in CIS patients, as
198opposed to a systemic response against a target antigen in
199the peripheral nervous system in GBS patients.
200In order to increase the probability of finding an intrathecal
201EBV-specific immune response, we also sought to examine
202whether an intrathecal production of EBV-specific IgM OCB
203may be present in CIS patients, since a recent study (Beltrán
t3:1 Table 3 Demographic, clinical,
MRI, CSF, and follow-up data of
EBV-specific IgG OCB positive
and negative CIS patients.
Significant results in bold.
t3:2 Variable Presence of EBV-
specific CSF-restricted
OCB (14 patients)
Absence of EBV-
specific CSF-restricted
OCB (36 patients)
p value
t3:3 Sex M/F 1/13 13/23 0.07
t3:4 Age at onset, years* 32 ± 8 33 ± 10 0.74
t3:5 Spinal onset, yes/no 5/9 13/23 1
t3:6 EDSS at onset* 1.9 ± 0.6 2.5 ± 1.1 0.03
t3:7 Complete recovery, yes/no 13/1 8/28 0.21
t3:8 Baseline brain MRI
t3:9 At least one lesion, yes/no
Presence of infratentorial lesions, yes/no
Presence of CE, yes/no
13/1
7/7
6/7
33/3
18/18
20/15
0.7
1
0.36
t3:10 Baseline spinal cord MRI
t3:11 Positive (at least one lesion), yes/no 6/7 20/15 0.4
t3:12 Total CSF protein* (normal value 15–45 mg/dl)
Elevated CSF protein yes/no, yes/no
35 ± 9
3/10
40 ± 13
10/23
0.34
0.46
t3:13 Cells* (normal value <4/mm3)
Elevated CSF cells yes/no, yes/no
3.9 ± 2.6
6/7
8.4 ± 8.8
24/11
0.04
0.14
t3:14 CSF/serum albumin* (normal value <6.5)
Elevated CSF serum/albumin, yes/no
3.8 ± 1.1
1/13
4.2 ± 1.4
2/32
0.21
0.65
t3:15 IgG index* (normal value <0.7)
Elevated IgG index yes/no, yes/no
1.1 ± 0.5
11/3
1.2 ± 0.6
34/1
0.97
0.07
t3:16 CDMS diagnosis at 1 year, yes/no
CDMS diagnosis at 3 years, yes/no
7/7
11/3
13/23
22/14
0.3
0.2
t3:17 EDSS at 3 years*
EDSS annual progression*
1.1 ± 1.2
0.19 ± 0.35
1.5 ± 1.3
0.25 ± 0.37
0.42
0.52
CE contrast enhancement
*Values expressed as mean ± SD
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204 et al. 2014) showed that there were no clonal overlaps between
205 the IgG and the IgM CSF repertoires, suggesting that IgM-
206 and IgG-producing B cells independently enter the intrathecal
207 compartment, and that they further mature and expand inde-
208 pendently of each other in the CSF without intrathecal isotype
209 switching from IgM to IgG. Furthermore, the majority of CSF
210 IgM OCB (in particular those directed against lipids and
211 which are thought to be secreted by CD5+ B cells) are persis-
212 tent and do not represent a transient primary immune response
213 (L. Villar et al. 2008). IgM OCB are present in approximately
214 40% ofMS patients and 20% of patients with CIS (Boscá et al.
215 2010; Ferraro et al. 2013). To our knowledge, however, this is
216 the first study assessing the presence of EBV-specific IgM
217 OCB inMS patients. Only a very small proportion of patients,
218 however, showed a positivity for EBV-specific IgM OCB
219 (6%), and, again, the frequency did not differ from that of
220 EBV-specific IgM OCB in control subjects with GBS.
221 Finally, data on high serum levels of anti-EBNA-1 or anti-
222 EBV-VCA IgG increasing the risk of developing MS in CIS
223 patients (Lünemann et al. 2010) and correlating with MRI
224 activity (Farrell et al. 2009; Lünemann et al. 2010), disability
225 (Lünemann et al. 2010) and brain atrophy (Zivadinov et al.
226 2009) in MS patients, prompted us to evaluate whether CIS
227 patients with positivity for EBV-specific IgG/IgM OCB
228 showed different clinical/CSF/MRI parameters or if they had
229 a worse prognosis in terms of conversion to MS and disability
230 during a 3-year follow-up, but our data did not support this
231 hypothesis.
232 Conclusion
233 There was no difference in the proportion of CIS and GB
234 patients with positivity for CSF anti-EBV-specific IgG or
235 IgM OCB. Furthermore, there were no correlations between
236 EBV-specific IgG/IgM OCB and CIS patients’ clinical, MRI,
237 and CSF parameters, nor did we find evidence for a prognostic
238 role of EBV-specific IgG/IgM OCB in CIS patients.
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